939 related articles for article (PubMed ID: 33541771)
1. Interaction of cannabidiol with other antiseizure medications: A narrative review.
Gilmartin CGS; Dowd Z; Parker APJ; Harijan P
Seizure; 2021 Mar; 86():189-196. PubMed ID: 33541771
[TBL] [Abstract][Full Text] [Related]
2. Breastfeeding while on treatment with antiseizure medications: a systematic review from the ILAE Women Task Force.
Tomson T; Battino D; Bromley R; Kochen S; Meador KJ; Pennell PB; Thomas SV
Epileptic Disord; 2022 Dec; 24(6):1020-1032. PubMed ID: 36193017
[TBL] [Abstract][Full Text] [Related]
3. Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies.
Strzelczyk A; Schubert-Bast S
CNS Drugs; 2022 Oct; 36(10):1079-1111. PubMed ID: 36194365
[TBL] [Abstract][Full Text] [Related]
4. Drug-drug interactions and pharmacodynamics of concomitant clobazam and cannabidiol or stiripentol in refractory seizures.
Klein P; Tolbert D; Gidal BE
Epilepsy Behav; 2019 Oct; 99():106459. PubMed ID: 31519475
[TBL] [Abstract][Full Text] [Related]
5. Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs.
Patsalos PN; Szaflarski JP; Gidal B; VanLandingham K; Critchley D; Morrison G
Epilepsia; 2020 Sep; 61(9):1854-1868. PubMed ID: 32918835
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis.
Talwar A; Estes E; Aparasu R; Reddy DS
Exp Neurol; 2023 Jan; 359():114238. PubMed ID: 36206805
[TBL] [Abstract][Full Text] [Related]
7. Short-term and long-term efficacy and safety of antiseizure medications in Lennox Gastaut syndrome: A network meta-analysis.
Devi N; Madaan P; Ameen R; Sahu JK; Bansal D
Seizure; 2022 Jul; 99():164-175. PubMed ID: 35487871
[TBL] [Abstract][Full Text] [Related]
8. Cannabidiol for the treatment of Lennox-Gastaut syndrome and Dravet syndrome: experts' recommendations for its use in clinical practice in Spain.
García-Peñas JJ; Gil Nagel-Rein A; Sánchez-Carpintero R; Villanueva-Haba V
Rev Neurol; 2021 Sep; 73(S01):S1-S8. PubMed ID: 34486101
[TBL] [Abstract][Full Text] [Related]
9. Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials.
Bialer M; Perucca E
Epilepsia; 2020 Jun; 61(6):1082-1089. PubMed ID: 32452568
[TBL] [Abstract][Full Text] [Related]
10. Cannabis for the Treatment of Epilepsy: an Update.
Gaston TE; Szaflarski JP
Curr Neurol Neurosci Rep; 2018 Sep; 18(11):73. PubMed ID: 30194563
[TBL] [Abstract][Full Text] [Related]
11. Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials.
Gunning B; Mazurkiewicz-Bełdzińska M; Chin RFM; Bhathal H; Nortvedt C; Dunayevich E; Checketts D
Acta Neurol Scand; 2021 Feb; 143(2):154-163. PubMed ID: 32969022
[TBL] [Abstract][Full Text] [Related]
12. Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes.
Chen JW; Borgelt LM; Blackmer AB
Ann Pharmacother; 2019 Jun; 53(6):603-611. PubMed ID: 30616356
[TBL] [Abstract][Full Text] [Related]
13. Neurocognitive Effects of Antiseizure Medications in Children and Adolescents with Epilepsy.
Besag FMC; Vasey MJ
Paediatr Drugs; 2021 May; 23(3):253-286. PubMed ID: 33956338
[TBL] [Abstract][Full Text] [Related]
14. Acute effect of cannabidiol on the activity of various novel antiepileptic drugs in the maximal electroshock- and 6 Hz-induced seizures in mice: Pharmacodynamic and pharmacokinetic studies.
Socała K; Wyska E; Szafarz M; Nieoczym D; Wlaź P
Neuropharmacology; 2019 Nov; 158():107733. PubMed ID: 31377197
[TBL] [Abstract][Full Text] [Related]
15. What has been the impact of new drug treatments on epilepsy?
Chen Z; Brodie MJ; Kwan P
Curr Opin Neurol; 2020 Apr; 33(2):185-190. PubMed ID: 32049739
[TBL] [Abstract][Full Text] [Related]
16. Clinical trial simulations of the interaction between cannabidiol and clobazam and effect on drop-seizure frequency.
Bergmann KR; Broekhuizen K; Groeneveld GJ
Br J Clin Pharmacol; 2020 Feb; 86(2):380-385. PubMed ID: 31657863
[TBL] [Abstract][Full Text] [Related]
17. Practical use of pharmaceutically purified oral cannabidiol in Dravet syndrome and Lennox-Gastaut syndrome.
Lattanzi S; Zaccara G; Russo E; La Neve A; Lodi MAM; Striano P
Expert Rev Neurother; 2021 Jan; 21(1):99-110. PubMed ID: 33026899
[TBL] [Abstract][Full Text] [Related]
18. An analysis of suicidal and self-injurious behavior reports with antiseizure medications in the FDA adverse event database.
Porwal MH; Razzak AN; Kumar V; Obeidat AZ; Sharma U
Epilepsy Res; 2024 Jul; 203():107382. PubMed ID: 38761467
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of antiseizure medication for Lennox-Gastaut syndrome: a systematic review and network meta-analysis.
Zhang L; Wang J; Wang C
Dev Med Child Neurol; 2022 Mar; 64(3):305-313. PubMed ID: 34590711
[TBL] [Abstract][Full Text] [Related]
20. Drug-induced liver injury associated with antiseizure medications from the FDA Adverse Event Reporting System (FAERS).
Kamitaki BK; Minacapelli CD; Zhang P; Wachuku C; Gupta K; Catalano C; Rustgi V
Epilepsy Behav; 2021 Apr; 117():107832. PubMed ID: 33626490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
